ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

MEDI Medimmune (MM)

0.00
0.00 (0.00%)
Share Name Share Symbol Market Type
Medimmune (MM) NASDAQ:MEDI NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0 -

MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Di

08/05/2007 6:01pm

PR Newswire (US)


Medimmune (NASDAQ:MEDI)
Historical Stock Chart


From Jun 2019 to Jun 2024

Click Here for more Medimmune Charts.
- Numax Achieves Primary Endpoint Among High-Risk Infants Versus Current Standard of Care and Shows Reduction of Medically Attended Outpatient RSV- Related Lower Respiratory Infections - TORONTO, May 8 /PRNewswire-FirstCall/ -- MedImmune, Inc. (NASDAQ:MEDI) today announced positive results from a large prospective trial conducted for prevention of respiratory syncytial virus (RSV). The trial compared motavizumab, the investigational monoclonal antibody (MAb) also known as Numax(R), with Synagis(R) (palivizumab), the standard of care for preventing RSV hospitalization in high-risk infants. In the Phase 3 study involving 6,635 pre-term infants at high risk for RSV, with a primary endpoint of non- inferiority, motavizumab demonstrated overall 26-percent fewer RSV hospitalizations compared with Synagis (p

1 Year Medimmune Chart

1 Year Medimmune Chart

1 Month Medimmune Chart

1 Month Medimmune Chart